Comparative Preclinical Evaluation of Tuznue Versus Referent Herceptin: A Registered Trastuzumab Biosimilar
Abstract Introduction The high cost of trastuzumab (Herceptin®) limits its accessibility for patients worldwide. Biosimilars, such as Tuznue® (HD201), represent a promising alternative to improve access to this essential therapy for HER2-positive breast cancer. This study aims to assess the similari...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Adis, Springer Healthcare
2025-04-01
|
| Schriftenreihe: | Drugs in R&D |
| Online-Zugang: | https://doi.org/10.1007/s40268-025-00505-w |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|